Quest Diagnostics Enters Material Definitive Agreement

Ticker: DGX · Form: 8-K · Filed: 2024-08-19T00:00:00.000Z

Sentiment: neutral

Topics: material-definitive-agreement, corporate-governance, fiscal-year-change

Related Tickers: DGX

TL;DR

Quest Diagnostics signed a big deal, amended bylaws, and changed its fiscal year.

AI Summary

Quest Diagnostics Incorporated announced on August 14, 2024, that it entered into a material definitive agreement. The company also reported amendments to its articles of incorporation or bylaws and a change in its fiscal year. The filing includes financial statements and exhibits.

Why It Matters

This filing indicates a significant contractual development for Quest Diagnostics, which could impact its operations, financial performance, and strategic direction.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks related to partnerships, acquisitions, or other significant business arrangements.

Key Players & Entities

FAQ

What type of material definitive agreement did Quest Diagnostics enter into?

The filing states that Quest Diagnostics Incorporated entered into a material definitive agreement, but the specific details of the agreement are not provided in this summary.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on August 14, 2024.

What changes were made to Quest Diagnostics' corporate structure or governance?

The filing indicates amendments to Quest Diagnostics' articles of incorporation or bylaws and a change in its fiscal year.

Where is Quest Diagnostics Incorporated's principal executive office located?

Quest Diagnostics Incorporated's principal executive office is located at 500 Plaza Drive, Secaucus, NJ 07094.

What is the Commission File Number for Quest Diagnostics Incorporated?

The Commission File Number for Quest Diagnostics Incorporated is 001-12215.

From the Filing

0001104659-24-090867.txt : 20240819 0001104659-24-090867.hdr.sgml : 20240819 20240819163330 ACCESSION NUMBER: 0001104659-24-090867 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20240814 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240819 DATE AS OF CHANGE: 20240819 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QUEST DIAGNOSTICS INC CENTRAL INDEX KEY: 0001022079 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 161387862 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12215 FILM NUMBER: 241221094 BUSINESS ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 BUSINESS PHONE: 9735202700 MAIL ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 FORMER COMPANY: FORMER CONFORMED NAME: CORNING CLINICAL LABORATORIES INC DATE OF NAME CHANGE: 19960903 8-K 1 tm2421254d4_8k.htm FORM 8-K false --12-31 0001022079 0001022079 2024-08-14 2024-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of Report (Date of Earliest Event Reported) : August 14, 2024     Quest Diagnostics Incorporated (Exact Name of Registrant as Specified in Its Charter)     Delaware (State or other jurisdiction of incorporation)   001-12215 16-1387862 (Commission File Number) (I.R.S. Employer Identification No.)     500 Plaza Drive Secaucus , NJ 07094 (Address of principal executive offices) (Zip Code)     ( 973 ) 520-2700 (Registrant's telephone number, including area code)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 Par Value DGX New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company   ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.        ¨             Item 1.01 Entry into a Material Definitive Agreement   On August 19, 2024, Quest Diagnostics Incorporated (the “Company”) issued $400,000,000 aggregate principal amount of 4.600% senior notes due 2027 (the “2027 Notes”), $600,000,000 aggregate principal amount of 4.625% senior notes due 2029 (the “2029 Notes”) and

View on Read The Filing